Another analyst, another thumbs-up
Wedbush just kept its Outperform rating on Adherex Technologies (NASDAQ:FENC) and stuck with a $13 price target. With the stock last trading around $6.49, that target implies a pretty chunky upside — the kind of math that makes bargain hunters sit up a little straighter.
Not exactly a unanimous parade
Here’s the twist: Wall Street isn’t marching in lockstep. MarketBeat says the broader consensus is still Moderate Buy with an average target of $14.80, but the name has also picked up a few stink-eye ratings along the way:
- Piper Sandler is more optimistic, with an $18 target
- B. Riley sits at $16
- Zacks Research recently cut the stock to Strong Sell
- Weiss is also in the skeptical camp
So yeah, the analyst crowd is basically split between “this could work” and “good luck with that.”
Why you should care
For investors, these calls don’t change the business overnight, but they can absolutely shape sentiment — especially for a low-priced stock where every upgrade or downgrade gets magnified like it’s starring in its own tiny soap opera. If enough firms keep pointing to upside, it can help keep buyers interested even when the stock is trading more on expectations than fundamentals.
Big picture: FENC is getting a fresh boost from Wedbush, but the stock still lives in that high-drama zone where analyst opinions matter almost as much as the company itself.